ErVimmune
Description
ErVimmune is a promising biotechnology company, founded in 2019 by Pr Stéphane Depil, with a unique approach to cancer immunotherapy. The company targets a family of tumor antigens derived from human endogenous retroviruses (HERVs), an untapped reservoir for tumor-specific antigens, abnormally expressed by tumor cells. By focusing on those antigens, ErVimmune has the potential to address the challenge of cold tumors with low mutational burden, which respond poorly to current immunotherapies. Armed with a platform based on proprietary data science techniques and generative AI, the company identified HERVs epitopes and validates them through proteomics and immunoassays.
